Duncan Walker

Duncan Walker

Company: OnKure Inc.

Job title: Chief Development Officer

Seminars:

The Novel, Next-Generation Class I-Selective HDAC Inhibitor OKI-179 shows Chemical Synthetic Lethality & Induces Regressions in combination with RAS-Pathway Inhibitors in Multiple RAS-Pathway-Mutated Cancers 10:30 am

The Class I-targeting HDAC inhibitor OKI-179 shows a chemical-synthetic lethality with RAS Pathway inhibitors, inducing cell killing in RAS-pathway-mutated cells as a result of inducing unrepaired dsDNA breaks OKI-179 combined with a RAS pathway inhibitor induces regressions in vivo, when the single-agent drugs alone are not effective, including tumour types with currently un-targetable RAS pathway…Read more

day: Day Two

Panel Discussion: Now We Have Successfully Targeted RAS G12C, What’s Next? 5:00 pm

As we close out two days dedicated to critical updates and project successes from across this community, this panel will dive into a discussion considering what is next for therapeutics targeting RAS-mutant cancers. After 40 years of dedicated science and significant progress, it is critical we expand the landscape of RAS targeted therapies beyond G12C…Read more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.